187 related articles for article (PubMed ID: 19841672)
1. Structural basis for substrate specificity in human monomeric carbonyl reductases.
Pilka ES; Niesen FH; Lee WH; El-Hawari Y; Dunford JE; Kochan G; Wsol V; Martin HJ; Maser E; Oppermann U
PLoS One; 2009 Oct; 4(10):e7113. PubMed ID: 19841672
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the substrate-binding site of human carbonyl reductases CBR1 and CBR3 by site-directed mutagenesis.
El-Hawari Y; Favia AD; Pilka ES; Kisiela M; Oppermann U; Martin HJ; Maser E
Chem Biol Interact; 2009 Mar; 178(1-3):234-41. PubMed ID: 19061875
[TBL] [Abstract][Full Text] [Related]
3. Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3.
Staab CA; Hartmanová T; El-Hawari Y; Ebert B; Kisiela M; Wsol V; Martin HJ; Maser E
Chem Biol Interact; 2011 May; 191(1-3):95-103. PubMed ID: 21256830
[TBL] [Abstract][Full Text] [Related]
4. Importance of the substrate-binding loop region of human monomeric carbonyl reductases in catalysis and coenzyme binding.
Miura T; Nishinaka T; Terada T
Life Sci; 2009 Aug; 85(7-8):303-8. PubMed ID: 19555696
[TBL] [Abstract][Full Text] [Related]
5. Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin.
Skarydová L; Skarka A; Novotná R; Zivná L; Martin HJ; Wsól V; Maser E
Toxicology; 2009 Oct; 264(1-2):52-60. PubMed ID: 19635524
[TBL] [Abstract][Full Text] [Related]
6. Carbonyl reductase.
Forrest GL; Gonzalez B
Chem Biol Interact; 2000 Dec; 129(1-2):21-40. PubMed ID: 11154733
[TBL] [Abstract][Full Text] [Related]
7. Human carbonyl reductases.
Malátková P; Maser E; Wsól V
Curr Drug Metab; 2010 Oct; 11(8):639-58. PubMed ID: 20942781
[TBL] [Abstract][Full Text] [Related]
8. Cloning and characterization of four rabbit aldo-keto reductases featuring broad substrate specificity for xenobiotic and endogenous carbonyl compounds: relationship with multiple forms of drug ketone reductases.
Endo S; Matsunaga T; Arai Y; Ikari A; Tajima K; El-Kabbani O; Yamano S; Hara A; Kitade Y
Drug Metab Dispos; 2014 Apr; 42(4):803-12. PubMed ID: 24510382
[TBL] [Abstract][Full Text] [Related]
9. Comparative anatomy of the aldo-keto reductase superfamily.
Jez JM; Bennett MJ; Schlegel BP; Lewis M; Penning TM
Biochem J; 1997 Sep; 326 ( Pt 3)(Pt 3):625-36. PubMed ID: 9307009
[TBL] [Abstract][Full Text] [Related]
10. Site-directed mutagenesis of residues in coenzyme-binding domain and active site of mouse lung carbonyl reductase.
Nakanishi M; Kaibe H; Matsuura K; Kakumoto M; Tanaka N; Nonaka T; Mitsui Y; Hara A
Adv Exp Med Biol; 1997; 414():555-61. PubMed ID: 9059662
[No Abstract] [Full Text] [Related]
11. Structure and function of 3 alpha-hydroxysteroid dehydrogenase.
Penning TM; Bennett MJ; Smith-Hoog S; Schlegel BP; Jez JM; Lewis M
Steroids; 1997 Jan; 62(1):101-11. PubMed ID: 9029723
[TBL] [Abstract][Full Text] [Related]
12. Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man.
Wsol V; Szotakova B; Martin HJ; Maser E
Toxicology; 2007 Sep; 238(2-3):111-8. PubMed ID: 17618725
[TBL] [Abstract][Full Text] [Related]
13. Human carbonyl reductase 1 participating in intestinal first-pass drug metabolism is inhibited by fatty acids and acyl-CoAs.
Hara A; Endo S; Matsunaga T; El-Kabbani O; Miura T; Nishinaka T; Terada T
Biochem Pharmacol; 2017 Aug; 138():185-192. PubMed ID: 28450226
[TBL] [Abstract][Full Text] [Related]
14. Engineering aldo-keto reductase 1B10 to mimic the distinct 1B15 topology and specificity towards inhibitors and substrates, including retinoids and steroids.
Giménez-Dejoz J; Weber S; Fernández-Pardo Á; Möller G; Adamski J; Porté S; Parés X; Farrés J
Chem Biol Interact; 2019 Jul; 307():186-194. PubMed ID: 31028727
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of 8-hydroxy-2-iminochromene derivatives as selective and potent inhibitors of human carbonyl reductase 1.
Hu D; Miyagi N; Arai Y; Oguri H; Miura T; Nishinaka T; Terada T; Gouda H; El-Kabbani O; Xia S; Toyooka N; Hara A; Matsunaga T; Ikari A; Endo S
Org Biomol Chem; 2015 Jul; 13(27):7487-99. PubMed ID: 26068795
[TBL] [Abstract][Full Text] [Related]
16. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.
O'connor T; Ireland LS; Harrison DJ; Hayes JD
Biochem J; 1999 Oct; 343 Pt 2(Pt 2):487-504. PubMed ID: 10510318
[TBL] [Abstract][Full Text] [Related]
17. Carbonyl reductase sniffer from the model organism daphnia: Cloning, substrate determination and inhibitory sensitivity.
Strehse JS; Protopapas N; Maser E
Chem Biol Interact; 2019 Jul; 307():29-36. PubMed ID: 30991043
[TBL] [Abstract][Full Text] [Related]
18. Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells.
Gavelová M; Hladíková J; Vildová L; Novotná R; Vondrácek J; Krcmár P; Machala M; Skálová L
Chem Biol Interact; 2008 Oct; 176(1):9-18. PubMed ID: 18755171
[TBL] [Abstract][Full Text] [Related]
19. Quantitative Analysis of mRNA and Protein Expression Levels of Aldo-Keto Reductase and Short-Chain Dehydrogenase/Reductase Isoforms in the Human Intestine.
Hirosawa K; Fujioka H; Morinaga G; Fukami T; Ishiguro N; Kishimoto W; Nakase H; Mizuguchi H; Nakajima M
Drug Metab Dispos; 2023 Dec; 51(12):1569-1577. PubMed ID: 37722844
[TBL] [Abstract][Full Text] [Related]
20. Involvement of two basic residues (Lys-17 and Arg-39) of mouse lung carbonyl reductase in NADP(H)-binding and fatty acid activation: site-directed mutagenesis and kinetic analyses.
Nakanishi M; Kakumoto M; Matsuura K; Deyashiki Y; Tanaka N; Nonaka T; Mitsui Y; Hara A
J Biochem; 1996 Aug; 120(2):257-63. PubMed ID: 8889808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
